Online citations, reference lists, and bibliographies.
← Back to Search

Updates On The Cytogenetics And Molecular Genetics Of Bone And Soft Tissue Tumors. Mesothelioma.

A. Sandberg, J. Bridge
Published 2001 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
This paper references
10.1038/370180A0
Open questions on p16
L. Bonetta (1994)
10.1136/oem.51.12.804
Malignant mesothelioma: attributable risk of asbestos exposure.
R. Spirtas (1994)
Chromosomal abnormalities in human malignant mesothelioma
S. Knuutila (1994)
Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): in vitro antiproliferative effects of a COX-2 inhibitor.
A. Marrogi (2000)
10.1159/000134125
A physical map of the region spanning the chromosome 12 translocation breakpoint in a mesothelioma with a t(X;12)(q22;p13).
J. Aerssens (1995)
p53 and Kirsten-ras mutations in human mesothelioma cell lines.
R. A. Metcalf (1992)
10.1002/(SICI)1097-4652(199908)180:2<150::AID-JCP2>3.0.CO;2-H
Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma
S. S. Murthy (1999)
10.1038/NM0897-908
Simian virus-40 large-T antigen binds p53 in human mesotheliomas
M. Carbone (1997)
10.1016/0046-8177(93)90080-Z
Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma.
R. Brown (1993)
10.1016/0165-4608(92)90159-6
del(6q) as a possible primary change in malignant mesothelioma.
A. Meloni (1992)
10.1016/S0092-8674(00)80781-3
Lack of BCL10 Mutations in Germ Cell Tumors and B Cell Lymphomas
J. Fakruddin (1999)
10.1002/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0
Angiogenic cytokines in mesothelioma: a study of VEGF, FGF‐1 and ‐2, and TGF β expression
S. Kumar-Singh (1999)
10.1200/JCO.2000.18.23.3912
Phase II study of vinorelbine in patients with malignant pleural mesothelioma.
J. Steele (2000)
10.1002/(SICI)1097-0142(20000225)90:1<55::AID-CNCR8>3.0.CO;2-P
Cytologic differential diagnosis among reactive mesothelial cells, malignant mesothelioma, and adenocarcinoma
H. Kitazume (2000)
10.1097/00000478-200104000-00027
Benign and malignant mesothelial proliferations.
L. Koss (2001)
Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha-receptors.
M. Versnel (1991)
Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma.
T. Taguchi (1993)
10.1097/00000478-200203000-00011
Expression of Telomerase Reverse Transcriptase (TERT) in Malignant Mesotheliomas
F. Kumaki (2002)
10.1093/CARCIN/11.4.673
Asbestos-related malignant mesothelioma: growth, cytology, tumorigenicity and consistent chromosome findings in cell lines from five patients.
K. Pelin-Enlund (1990)
10.1002/1097-0142(19860515)57:10<1905::AID-CNCR2820571003>3.0.CO;2-J
Mesothelioma and mineral fibers
J. Wagner (1986)
10.1093/JNCI/87.24.1870
Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma.
R. Kratzke (1995)
10.1073/PNAS.90.11.5100
Physical and functional interaction between WT1 and p53 proteins.
S. Maheswaran (1993)
10.1038/NG0893-415
The Wilms tumour gene WT1 is expressed in murine mesoderm–derived tissues and mutated in a human mesothelioma
S. Park (1993)
10.1016/S0165-4608(97)00368-3
Translocation (3;3)(p14;q29) as the primary chromosome abnormality in a peritoneal mesothelioma.
M. Teixeira (1998)
10.1172/JCI119010
Asbestos induces apoptosis of human and rabbit pleural mesothelial cells via reactive oxygen species.
V. Broaddus (1996)
10.3892/IJO.14.1.181
Somatic genetic alterations in human malignant mesothelioma (review).
W. Lee (1999)
10.1002/1097-0215(200002)9999:9999<::AID-IJC1094>3.0.CO;2-M
Gene expression profiling of malignant mesothelioma cell lines: cDNA array study
E. Kettunen (2001)
10.1002/(SICI)1097-4652(199908)180:2<167::AID-JCP4>3.0.CO;2-Q
New molecular and epidemiological issues in mesothelioma: Role of SV40
M. Carbone (1999)
10.1126/SCIENCE.8153634
A cell cycle regulator potentially involved in genesis of many tumor types.
A. Kamb (1994)
10.1002/PATH.1711750210
Detection of numerical chromosomal aberrations in paraffin‐embedded malignant pleural mesothelioma by non‐isotopic in situ hybridization
K. Segers (1995)
10.1016/S0165-4608(00)00420-9
DNA copy number changes in familial malignant mesothelioma.
V. Ascoli (2001)
10.1016/S1092-9134(00)90036-4
Mitotic and in situ end-labeling apoptotic indices as prognostic markers in malignant mesothelioma.
T. Beer (2000)
10.1097/00000478-200009000-00001
The separation of benign and malignant mesothelial proliferations.
A. Churg (2000)
10.1093/JNCI/88.24.1853
Glutathione S-transferase and N-acetyltransferase genotypes and asbestos-associated pulmonary disorders.
A. Hirvonen (1996)
10.1111/j.1365-2559.1993.tb00140.x
The frequency of p53 immunostaining in asbestos‐associated mesotheliomas and non‐asbestos‐associated mesotheliomas
F. Mayall (1993)
SV40 induces mesotheliomas in hamsters.
C. Cicala (1993)
10.1016/S0046-8177(99)90011-4
The immunohistochemical diagnosis of epithelial mesothelioma.
N. Ordóñez (1999)
Nonrandom chromosome alterations in human malignant mesothelioma.
N. Popescu (1988)
10.1002/1098-2264(2000)9999:9999<::AID-GCC1059>3.0.CO;2-7
Absence of post‐transcriptional RNA modifications of BCL10 in human malignant mesothelioma and colorectal cancer
Sinoula Apostolou (2001)
Establishment of a human in vitro mesothelial cell model system for investigating mechanisms of asbestos-induced mesothelioma.
Y. Ke (1989)
10.1073/PNAS.91.6.2156
Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization.
A. Kallioniemi (1994)
Genetic alterations of the p53 gene are a feature of malignant mesotheliomas.
R. Cote (1991)
10.1016/S0165-4608(97)00001-0
Comparative genomic hybridization study on pooled DNAs from tumors of one clinical-pathological entity.
S. Knuutila (1998)
10.1038/bjc.1989.326
Chromosomal abnormalities and their correlations with asbestos exposure and survival in patients with mesothelioma.
M. Tiainen (1989)
10.1002/1098-2264(2000)9999:9999<::AID-GCC1019>3.0.CO;2-B
Simian virus‐40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma
A. Procopio (2000)
10.1002/(SICI)1096-9896(199701)181:1<67::AID-PATH723>3.0.CO;2-Z
WT1 MUTATION IN MALIGNANT MESOTHELIOMA AND WT1 IMMUNOREACTIVITY IN RELATION TO p53 AND GROWTH FACTOR RECEPTOR EXPRESSION, CELL‐TYPE TRANSITION, AND PROGNOSIS
S. Kumar-Singh (1997)
10.1165/AJRCMB.12.5.7742009
The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma.
D. FitzPatrick (1995)
10.1002/1097-0142(20010401)91:7<1349::AID-CNCR1138>3.0.CO;2-D
Expression and prognostic significance of catalase in malignant mesothelioma
K. Kahlos (2001)
10.1093/jnci/92.6.496
Response: More About: Cell and Molecular Biology of Simian Virus 40: Implications for Human Infections and Disease.
J. Butel (2000)
10.1038/sj.onc.1204199
Control of cell cycle progression in human mesothelioma cells treated with gamma interferon
C. Vivo (2001)
10.1016/S1525-1578(10)60639-3
Severe chromosomal aberrations in pleural mesotheliomas with unusual mesodermal features. Comparative genomic hybridization evidence for a mesothelioma subgroup.
M. Krismann (2000)
The role of immunohistochemistry in the diagnosis of malignant mesothelioma.
C. Moran (2000)
10.1056/NEJM199102143240702
Diagnostic relevance of clonal cytogenetic aberrations in malignant soft-tissue tumors.
J. Fletcher (1991)
Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma.
K. Amin (1995)
p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma.
J. Cheng (1994)
Further validation of SV40-like DNA in human pleural mesotheliomas.
H. Pass (1998)
10.1016/S0092-8674(02)09765-9
Absence of BCL10 Mutations in Human Malignant Mesothelioma
Sinoula Apostolou (1999)
10.1073/PNAS.92.10.4517
G1 phase arrest induced by Wilms tumor protein WT1 is abrogated by cyclin/CDK complexes.
T. Kudoh (1995)
10.1001/JAMA.1968.03140240065025
Asbestos and mesothelioma.
M. Godwin (1968)
10.1038/375691A0
Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein
K. Martin (1995)
10.1002/IJC.2910630304
Lung carcinoma and malignant mesothelioma in patients exposed to thorotrast: Incidence, histology and p53 status
M. Andersson (1995)
10.1002/GCC.2870070108
Molecular deletion of 9p sequences in non‐small cell lung cancer and malignant mesothelioma
R. Center (1993)
10.1007/s004320050171
Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma
E. Tolnay (1998)
10.1097/00000478-200004000-00016
Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma.
N. Ordóñez (2000)
Detection of SV40 sequences in human mesothelioma.
D. Griffiths (1998)
10.1016/S0165-4608(97)90239-9
Mesothelioma and lung carcinomas
Anna-Maria Björkqvist (1997)
10.1002/(SICI)1098-2264(199903)24:3<238::AID-GCC9>3.0.CO;2-M
Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: Evidence for a two‐hit mechanism of NF2 inactivation
J. Cheng (1999)
10.1002/1097-0215(200002)9999:9999<::AID-IJC1102>3.0.CO;2-Y
Expression and activity of matrix metalloproteases in human malignant mesothelioma cell lines
Z. Liu (2001)
10.1002/(SICI)1097-0215(20000301)85:5<743::AID-IJC24>3.0.CO;2-3
Presence of simian virus 40 sequences in malignant pleural, peritoneal and noninvasive mesotheliomas
N. Shivapurkar (2000)
10.1038/sj.bjc.6690105
The European mesothelioma epidemic
J. Peto (1999)
10.1136/jcp.52.4.291
Mutations of p53 gene and SV40 sequences in asbestos associated and non-asbestos-associated mesotheliomas.
F. Mayall (1999)
10.1053/HP.2000.6552
NCAM (neural cell adhesion molecules) expression in malignant mesotheliomas.
S. Lantuéjoul (2000)
10.3109/07357909609018904
Mechanisms of carcinogenesis and clinical features of asbestos-associated cancers.
B. Mossman (1996)
10.1016/S0165-4608(96)00164-1
Translocation (2;3)(p21;p26) as the sole anomaly in a benign localized fibrous mesothelioma.
F. Mertens (1996)
10.1016/0165-4608(95)00358-4
Gains and losses of DNA sequences in malignant mesothelioma by comparative genomic hybridization.
P. Kivipensas (1996)
A multi-institutional study confirms the presence and expression of simian virus 40 in human malignant mesotheliomas.
J. Testa (1998)
10.1136/mp.51.2.113
Absence of HHV-8 DNA sequences in malignant mesothelioma.
V. Ascoli (1998)
10.1093/AJCP/110.3.397
Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review.
D. Henderson (1998)
10.1093/OXFORDJOURNALS.AJE.A009093
Analysis of current trends in United States mesothelioma incidence.
B. Price (1997)
10.1002/PATH.1711680406
Immunoreactivity for p53 protein in malignant mesothelioma and non‐neoplastic mesothelium
M. Ramael (1992)
SV40, JC and BK expression in tissue, urine and blood samples from patients with malignant and nonmalignant pleural disease.
L. Strizzi (2000)
10.1093/JNCI/72.4.823
Chromosome changes in soft tissue sarcomas.
R. Becher (1984)
10.1016/0165-4608(91)90245-P
Translocation X;12 in mesothelioma.
P. Dal Cin (1991)
Serum-dependent growth patterns of two, newly established human mesothelioma cell lines.
J. Klominek (1989)
The chromosomes in human cancer and leukemia
A. Sandberg (1990)
10.1016/0165-4608(90)90258-C
Cytogenetic analysis of malignant mesothelioma.
A. Hagemeijer (1990)
Comparative genomic hybridization and loss of heterozygosity analyses identify a common region of deletion at 15q11.1-15 in human malignant mesothelioma.
B. Balsara (1999)
Codeletion of p15 and p16 in primary malignant mesothelioma.
S. Xio (1995)
10.1002/(SICI)1097-0215(19970917)72:6<1034::AID-IJC19>3.0.CO;2-4
Differential motile response of human malignant mesothelioma cells to fibronectin, laminin and collagen type IV: The role of β1 integrins
J. Klominek (1997)
10.1289/EHP.97105S51069
Susceptibility of p53-deficient mice to induction of mesothelioma by crocidolite asbestos fibers.
J. Marsella (1997)
Homozygous deletions within 9p21-p22 identify a small critical region of chromosomal loss in human malignant mesotheliomas.
J. Cheng (1993)
Wilms' tumor suppressor gene expression in rat and human mesothelioma.
C. Walker (1994)
10.1038/bjc.1998.42
Comparison of DNA copy number changes in malignant mesothelioma, adenocarcinoma and large-cell anaplastic carcinoma of the lung.
A. M. Björkqvist (1998)
Deletions of chromosome 4 at multiple sites are frequent in malignant mesothelioma and small cell lung carcinoma.
N. Shivapurkar (1999)
10.1002/(SICI)1098-2744(199910)26:2<93::AID-MC4>3.0.CO;2-Z
Simian virus 40 (SV40)–like DNA sequences not detectable in Finnish mesothelioma patients not exposed to SV40‐contaminated polio vaccines
A. Hirvonen (1999)
10.1182/BLOOD.V74.3.940.BLOODJOURNAL743940
Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines in vitro.
G. Demetri (1989)
10.1016/0046-8177(93)90079-V
The search for the optimal immunohistochemical panel for the diagnosis of malignant mesothelioma.
L. Weiss (1993)
10.1038/bjc.1996.585
High levels of MDM2 are not correlated with the presence of wild-type p53 in human malignant mesothelioma cell lines.
S. Ungar (1996)
10.1136/thx.54.7.638
The molecular basis of asbestos induced lung injury
D. Kamp (1999)
Normal human mesothelial cells and mesothelioma cell lines express insulin-like growth factor I and associated molecules.
T. Lee (1993)
Molecular biology studies on mesothelioma tumor samples: preliminary data on H-ras, p21, and SV40.
A. Cristaudo (1995)
10.1136/thx.54.1.60
Simian virus 40 and human pleural mesothelioma
C. Mulatero (1999)
10.1016/0165-4608(93)90174-K
Karyotypic changes in the preclinical and subsequent stages of malignant mesothelioma: a case report.
I. Hansteen (1993)
The Mesothelial Cell and Mesothelioma
J. Bignon (1994)
10.1038/sj.onc.1201870
Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression
S. Frizelle (1998)
10.1111/J.1601-5223.1986.TB00667.X
Chromosomes and chromosomal evolution in human mesotheliomas as reflected in sequential analyses of two cases.
G. Stenman (1986)
10.1002/1098-2264(200007)28:3<337::AID-GCC12>3.0.CO;2-B
Loss of heterozygosity analysis of 13q and 14q in human malignant mesothelioma
A. De Rienzo (2000)
10.3892/IJO.15.3.437
Modulation of integrin expression on mesotheliomas: the role of different histotypes in invasiveness.
A. Giuffrida (1999)
10.1002/(SICI)1097-0215(19980209)75:4<649::AID-IJC25>3.0.CO;2-2
The gene for the cyclin‐dependent‐kinase‐4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma
J. Prins (1998)
10.1007/BF00199393
Immunoreactivity for p53 and mdm2 and the detection of p53 mutations in human malignant mesothelioma
K. Segers (2004)
10.1093/CARCIN/14.8.1597
Gap junctional intercellular communication of primary and asbestos-associated malignant human mesothelial cells.
K. Linnainmaa (1993)
10.1002/(SICI)1096-9896(199803)184:3<252::AID-PATH15>3.0.CO;2-R
SV40‐like DNA sequences in pleural mesothelioma, bronchopulmonary carcinoma, and non‐malignant pulmonary diseases
F. Galateau-Sallé (1998)
10.1126/SCIENCE.2153315
Asbestos: scientific developments and implications for public policy.
B. Mossman (1990)
Inherited GSTM1 and NAT2 defects as concurrent risk modifiers in asbestos-related human malignant mesothelioma.
A. Hirvonen (1995)
Recurrent chromosome 6 abnormalities in malignant mesothelioma.
M. Ribotta (1998)
10.1038/bjc.1997.91
Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma.
A. Björkqvist (1997)
10.1002/GCC.2870110104
Loss of heterozygosity on the short arm of chromosome 3 in mesothelioma cell lines and solid tumors
M. Zeiger (1994)
10.1002/IJC.2910510220
Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: Interleukin‐6 production as a common feature
D. Schmitter (1992)
10.1378/CHEST.116.SUPPL_3.455S
Emerging translational therapies for mesothelioma.
H. Pass (1999)
10.1038/sj.onc.1203322
Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma
S. Murthy (2000)
10.1111/j.1365-2559.1992.tb00403.x
p53 expression is common in malignant mesothelioma
G. Kafiri (1992)
10.1073/PNAS.92.24.10854
High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas.
A. Bianchi (1995)
10.1016/S0046-8177(99)90066-7
Expression of E-cadherin in bone and soft tissue sarcomas: a possible role in epithelial differentiation.
H. Sato (1999)
Identification par dénaturation thermique ménagée des anomalies chromosomiques observées dans six tumeurs métastatiques humaines
N. Ayraud (1975)
10.1016/0165-4608(92)90258-A
Interphase cytogenetics on paraffin sections of malignant pleural mesothelioma. A comparison to conventional karyotyping and flow cytometric studies.
M. Tiainen (1992)
10.1093/PPR/114.1.S68
Cytopathology of pleural mesotheliomas.
G. Nguyen (2000)
10.1016/0959-8049(92)90523-5
Malignant mesothelioma: clinical characteristics, asbestos mineralogy and chromosomal abnormalities of 41 patients.
L. Tammilehto (1992)
10.1002/CYTO.990190111
Prognostic significance of DNA aneuploidy in diffuse malignant mesothelioma.
H. Isobe (1995)
10.1126/SCIENCE.8023167
Rates of p16 (MTS1) mutations in primary tumors with 9p loss.
P. Cairns (1994)
10.1289/EHP.97105S51147
Crocidolite asbestos induces apoptosis of pleural mesothelial cells: role of reactive oxygen species and poly(ADP-ribosyl) polymerase.
V. Broaddus (1997)
10.1002/(SICI)1097-0215(19980413)76:2<240::AID-IJC12>3.0.CO;2-G
Hepatocyte growth factor/scatter factor stimulates chemotaxis and growth of malignant mesothelioma cells through c‐met receptor
J. Klominek (1998)
Cancer risk associated with simian virus 40 contaminated polio vaccine.
S. Fisher (1999)
10.1165/AJRCMB.16.1.8998073
Absence of p53 mutations in malignant mesotheliomas.
O. Mor (1997)
Loss of heterozygosity analysis defines a critical region in chromosome 1p22 commonly deleted in human malignant mesothelioma.
W. Lee (1996)
Simian virus 40 and pleural mesothelioma in humans.
H. Strickler (1996)
Simian virus 40-like DNA sequences in human pleural mesothelioma.
M. Carbone (1994)
10.1097/00000478-199609000-00001
Calretinin: a novel immunocytochemical marker for mesothelioma.
C. Doglioni (1996)
Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma.
Y. Soini (1999)
Chemotaxis and haptotaxis of human malignant mesothelioma cells: effects of fibronectin, laminin, type IV collagen, and an autocrine motility factor-like substance.
J. Klominek (1993)
10.1097/00000421-199102000-00024
Accomplishments in cancer research
J. Fortner (1991)
10.1016/0165-4608(86)90074-9
Chromosome changes in malignant mesothelioma.
Z. Gibas (1986)
10.1002/(SICI)1097-0215(19980812)77:4<554::AID-IJC14>3.0.CO;2-6
Heterogeneity of mesothelioma cell lines as defined by altered genomic structure and expression of the NF2 gene
B. Deguen (1998)
10.1093/CARCIN/15.11.2673
Expression of cell adhesion molecules and connexins in gap junctional intercellular communication deficient human mesothelioma tumour cell lines and communication competent primary mesothelial cells.
K. Pelin (1994)
10.1038/NM0897-913
The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas
A. Luca (1997)
Multiple regions of allelic loss from chromosome arm 6q in malignant mesothelioma.
D. Bell (1997)
Cytogenetics of Bone and Soft Tissue Tumors
A. Sandberg (1995)
10.1136/thx.51.11.1074
Simian virus 40 large T antigen (SV40LTAg) primer specific DNA amplification in human pleural mesothelioma tissue.
C. Pepper (1996)
[Identification by means of heat denaturation of chromosome aberrations in 6 human metastatic tumors].
N. Ayraud (1975)
Antisense to SV40 early gene region induces growth arrest and apoptosis in T-antigen-positive human pleural mesothelioma cells.
I. Waheed (1999)
10.1002/(SICI)1098-2744(199701)18:1<54::AID-MC7>3.0.CO;2-R
Characterization of the rat neurofibromatosis 2 gene and its involvement in asbestos‐induced mesothelioma
E. Kleymenova (1997)
10.1006/GENO.1994.1136
Regional assignment of seven loci to 12p13.2-pter by PCR analysis of somatic cell hybrids containing the der(12) or the der(X) chromosome from a mesothelioma showing t(X;12)(q22;p13).
J. Aerssens (1994)
Cytogenetic analysis of effusions from malignant mesothelioma. A diagnostic adjunct to cytology.
R. Granados (1994)
10.1016/0169-5002(95)90162-0
Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer.
Y. Sekido (1995)
10.1073/PNAS.92.24.10819
Asbestos and mesothelioma: genetic lessons from a tragedy.
A. Knudson (1995)
10.1046/j.1365-2559.2000.00981.x
Anti‐mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms
R. Attanoos (2000)
10.1038/modpathol.3880018
Value of the Mesothelium-Associated Antibodies Thrombomodulin, Cytokeratin 5/6, Calretinin, and CD44H in Distinguishing Epithelioid Pleural Mesothelioma from Adenocarcinoma Metastatic to the Pleura
P. Cury (2000)
10.1165/AJRCMB.19.3.2884
Tenascin and fibronectin expression in human mesothelial cells and pleural mesothelioma cell-line cells.
V. Kinnula (1998)
10.1002/(SICI)1097-0142(19990425)87:2<83::AID-CNCR7>3.0.CO;2-S
N‐cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas
Aaron C. Han (1999)
10.1002/GCC.2870010207
Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: Possible sites of tumor suppressor genes
W. Flejter (1989)
10.1016/0165-4608(88)90035-0
Nonrandom chromosomal abnormalities in malignant pleural mesothelioma.
M. Tiainen (1988)
10.1038/NM0897-839
An old acquaintance resurfaces in human mesothelioma
K. Wiman (1997)
10.1002/GCC.2870090114
Deletion mapping of the short arm of chromosome 3 in human malignant mesothelioma
You Yong Lu (1994)
10.1016/0165-4608(94)90447-2
Expression of the Wilms' tumour gene WT 1 in human malignant mesothelioma cell lines
A. W. Langerak (1994)
10.1038/sj.onc.1201375
Simian virus 40, poliovaccines and human tumors: a review of recent developments
M. Carbone (1997)
10.1097/00000372-198502000-00022
Soft Tissue Tumors
J. B. Stern (1985)



This paper is referenced by
10.1046/j.1440-1827.2003.01588.x
Deciduoid mesothelioma in the pelvic cavity
S. Maeda (2004)
10.1080/01913120500313135
Mesothelioma, Mesothelial Proliferations, and Their Mimics: A Multimodal Approach—Society for Ultrastructural Pathology Companion Meeting at United States and Canadian Academy of Pathology Annual Session in San Antonio, February 2005
J. Hicks (2006)
10.1186/1471-2407-10-54
In vitro and in vivo characterization of highly purified Human Mesothelioma derived cells
A. Melotti (2009)
10.1016/j.ijsu.2015.02.015
Multimodal treatment of abdominal and pelvic desmoplastic small round cell tumor with relative good prognosis.
Yuhong Tang (2015)
10.1080/01913120500313168
Biologic, Cytogenetic, and Molecular Factors in Mesothelial Proliferations
J. Hicks (2006)
10.1002/ijc.10996
Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF‐C autocrine loops
R. Masood (2003)
10.1038/modpathol.3800775
SYT-SSX fusion is absent in sarcomatoid mesothelioma allowing its distinction from synovial sarcoma of the pleura
N. Weinbreck (2007)
10.1016/J.CANCERGENCYTO.2006.04.011
Cytogenetic and molecular genetic changes in malignant mesothelioma.
M. Musti (2006)
10.2217/fon.09.7
Malignant pleural mesothelioma.
R. Stahel (2009)
10.1007/s10585-004-3150-2
Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma
B. Davidson (2004)
10.1158/1055-9965.EPI-04-0903
A Molecular Epidemiology Case Control Study on Pleural Malignant Mesothelioma
C. Bolognesi (2005)
10.1016/j.humpath.2016.04.015
Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization array.
P. Chirac (2016)
10.1016/B978-0-323-44732-4.00023-6
Disorders of the Peritoneum
J. Watkins (2018)
10.1016/J.LUNGCAN.2003.11.014
Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma.
B. Davidson (2004)
10.1002/AJMG.10691
Cytogenetics and molecular genetics of bone and soft-tissue tumors.
A. Sandberg (2002)
10.1016/J.LUNGCAN.2005.03.019
Apoptosis regulation and drug resistance in malignant pleural mesothelioma.
U. Zangemeisterwittke (2005)
10.1016/J.RPPNEU.2012.02.004
Mesotelioma deciduóide pleural --- uma entidade rara numa mulher jovem
Cláudia Santos (2012)
10.1007/s10143-015-0663-x
The molecular aspects of chordoma
Sukru Gulluoglu (2015)
10.5858/arpa.2011-0215-RA
Molecular changes in mesothelioma with an impact on prognosis and treatment.
D. Jean (2012)
10.1007/3-540-30792-3_7
Cytogenetics and Molecular Genetics of Soft Tissue Tumors and Bone Tumors
A. Sandberg (2006)
10.1002/cncy.21392
Claudin‐4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology
V. Jo (2014)
10.1016/j.ccr.2008.01.030
A conditional mouse model for malignant mesothelioma.
J. Jongsma (2008)
The hedgehog pathway on malignant mesothelioma
C. Lim (2015)
Title BRAF and NRAS mutations are uncommon in melanomasarising in diverse internal organs
Yao Shan Fan (2005)
10.1016/j.ajpath.2010.10.039
Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma.
D. Jean (2011)
10.1007/S11912-002-0006-2
Current therapy for malignant mesothelioma
W. Smythe (2002)
10.1002/DC.20296
Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities
R. Reich (2005)
Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.
P. Illei (2003)
10.1038/s41379-019-0330-9
Molecular characterization of localized pleural mesothelioma
Y. Hung (2019)
10.1038/sj.onc.1208263
Aberrant methylation profile of human malignant mesotheliomas and its relationship to SV40 infection
M. Suzuki (2005)
10.1159/000113504
Characterization of Human Mesothelioma Cell Lines as Tumor Models for Suicide Gene Therapy
M. Veldwijk (2008)
10.1038/nrc1168
Mechanisms of sarcoma development
L. Helman (2003)
See more
Semantic Scholar Logo Some data provided by SemanticScholar